Ladenburg analyst Jeffrey Cohen downgraded Bionano Genomics (BNGO) to Neutral from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics Sees Growth in OGM Adoption
- Bionano Genomics reports Q3 revenue $6.1M, consensus $7.85M.
- Options Volatility and Implied Earnings Moves Today, November 13, 2024
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- BNGO Earnings this Week: How Will it Perform?